**Protocol for the Examination of Cystectomy Specimens From Patients With Carcinoma of the Urinary Bladder**

**Version:** 4.2.0.0

**Protocol Posting Date:** September 2023

**CAP Laboratory Accreditation Program Protocol Required Use Date:** June 2024

The changes included in this current protocol version affect accreditation requirements. The new deadline for implementing this protocol version is reflected in the above accreditation date.

**For accreditation purposes, this protocol should be used for the following procedures AND tumor types:**

|  |  |
| --- | --- |
| **Procedure** | **Description** |
| Cystectomy | Includes specimens designated partial, total, or radical cystectomy, radical cystoprostatectomy (for bladder cancer), and anterior pelvic exenterations |
| **Tumor Type** | **Description** |
| Carcinomas | Includes invasive carcinomas of the urinary bladder, including urothelial carcinoma, its morphological subtypes, and other carcinoma such as squamous cell carcinoma, adenocarcinoma, Mϋllerian carcinoma, neuroendocrine carcinoma# |

# This protocol is recommended for reporting noninvasive urothelial tumors (papillary and flat), but it is not required for accreditation purposes.

**This protocol is NOT required for accreditation purposes for the following:**

|  |
| --- |
| **Procedure** |
| Biopsy, transurethral resection of the bladder tumor# (TURBT), or enucleations (consider Urinary Bladder Biopsy/TURBT protocol) |
| Primary resection specimen with no residual cancer (e.g., following neoadjuvant therapy) |
| Cytologic specimens |

# Transurethral resection of a bladder tumor is NOT considered to be the definitive resection specimen, even though the entire cancer may be removed.

**The following tumor types should NOT be reported using this protocol:**

|  |
| --- |
| **Tumor Type** |
| Urachal Carcinoma |
| Lymphoma (consider the Lymphoid Neoplasm protocols) |
| Sarcoma (consider the Soft Tissue protocol) |

**Authors**

Lara R. Harik, MD, FCAP\*; Gladell P. Paner, MD, FCAP\*; Hikmat A. Al-Ahmadie, MD; Robert W. Allan, MD; Mahul B. Amin, MD; Mehmet Asim Bilen, MD; Bernard H. Bochner, MD; Charles C. Guo, MD; Antonio Lopez-Beltran, MD, PhD; Jesse K. McKenney, MD; Ankur R. Sangoi, MD; S. Joseph Sirintrapun, MD; Roxanne Wadia, MD; Sara E. Wobker, MD; Ming Zhou, MD, PhD.  
With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.  
\* Denotes primary author.

**Accreditation Requirements**

This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

* Core data elements are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is “not applicable” or “cannot be determined.”
* Conditional data elements are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.
* Optional data elements are identified with “+” and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (ie, secondary consultation, second opinion, or review of outside case at second institution).

**Synoptic Reporting**

All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

* Data element: followed by its answer (response), outline format without the paired Data element: Response format is NOT considered synoptic.
* The data element should be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including “Cannot be determined” if appropriate.
* Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
  + Anatomic site or specimen, laterality, and procedure
  + Pathologic Stage Classification (pTNM) elements
  + Negative margins, as long as all negative margins are specifically enumerated where applicable
* The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location

Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report ie, all required elements must be in the synoptic portion of the report in the format defined above.

**Summary of Changes**

**v 4.2.0.0**

* WHO 5th Edition update to content and Explanatory Notes
* pTNM Classification update to content and Explanatory Note
* LVI question update from “Lymphovascular Invasion” to “Lymphatic and/or Vascular Invasion"

**Reporting Template**

**Protocol Posting Date: September 2023**

**Select a single response unless otherwise indicated.**

**CASE SUMMARY: (URINARY BLADDER: Cystectomy, Anterior Exenteration)**

**Standard(s)**: AJCC-UICC 8

*This protocol is recommended for reporting noninvasive urothelial tumors (papillary and flat), but it is not required for accreditation purposes.*

**SPECIMEN (Note** [**A**](#N7682)**)**

**Procedure**

\_\_\_ Partial cystectomy

\_\_\_ Radical cystectomy (total cystectomy)

\_\_\_ Radical cystoprostatectomy

\_\_\_ Anterior pelvic exenteration

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not specified

**TUMOR**

**Tumor Site (select all that apply)**

\_\_\_ Trigone

\_\_\_ Right lateral wall

\_\_\_ Left lateral wall

\_\_\_ Anterior wall

\_\_\_ Posterior wall

\_\_\_ Dome

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Histologic Type (Note** [**B**](#N7683)**) (select all that apply)**

*Urothelial*

\_\_\_ Papillary urothelial carcinoma, noninvasive

\_\_\_ Urothelial carcinoma in situ

\_\_\_ Urothelial carcinoma, invasive (conventional)

\_\_\_ Urothelial carcinoma, micropapillary

\_\_\_ Urothelial carcinoma, nested

\_\_\_ Urothelial carcinoma, tubular and microcystic

\_\_\_ Urothelial carcinoma, lymphoepithelioma-like

\_\_\_ Urothelial carcinoma, plasmacytoid

\_\_\_ Urothelial carcinoma, sarcomatoid

\_\_\_ Urothelial carcinoma, giant cell

\_\_\_ Urothelial carcinoma, poorly differentiated

\_\_\_ Urothelial carcinoma, lipid-rich

\_\_\_ Urothelial carcinoma, clear cell (glycogen-rich)

\_\_\_ Urothelial carcinoma with squamous differentiation

\_\_\_ Urothelial carcinoma with glandular differentiation

\_\_\_ Urothelial carcinoma with trophoblastic differentiation

\_\_\_ Urothelial carcinoma with Müllerian differentiation

*Squamous*

\_\_\_ Squamous cell carcinoma

\_\_\_ Verrucous carcinoma

\_\_\_ Squamous cell carcinoma in situ (no invasive carcinoma identified)

*Glandular*

\_\_\_ Adenocarcinoma, NOS

\_\_\_ Adenocarcinoma, enteric

\_\_\_ Adenocarcinoma, mucinous

\_\_\_ Adenocarcinoma, mixed

\_\_\_ Adenocarcinoma, signet-ring cell

\_\_\_ Adenocarcinoma in situ (no invasive carcinoma identified)

*Müllerian*

\_\_\_ Clear cell adenocarcinoma

\_\_\_ Endometrioid carcinoma

*Neuroendocrine*

\_\_\_ Small cell neuroendocrine carcinoma

\_\_\_ Large cell neuroendocrine carcinoma

\_\_\_ Well-differentiated neuroendocrine tumor

\_\_\_ Other histologic type not listed (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Carcinoma, type cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Specify Percentages of Histologic Subtypes and Divergent Differentiations Present (totaling 100%)#  (select all that apply)**

*# Applicable for mixed subtypes, divergent differentiations, and other carcinomas*

\_\_\_ Urothelial carcinoma, invasive (conventional): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, micropapillary: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, nested: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, large nested: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, tubular and microcystic: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, lymphoepithelioma-like: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, plasmacytoid: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, sarcomatoid: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, giant cell: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, poorly differentiated: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Urothelial carcinoma, lipid-rich: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Clear cell (glycogen-rich): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Squamous differentiation: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Glandular (adenocarcinoma) differentiation: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Trophoblastic differentiation: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Müllerian differentiation: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Small cell neuroendocrine carcinoma: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Large cell neuroendocrine carcinoma: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Histologic Type Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Histologic Grade (Note** [**C**](#N7684)**)**

*For urothelial carcinoma, other variants, or divergent differentiation*

\_\_\_ Low-grade

\_\_\_ High-grade

*For squamous cell carcinoma or adenocarcinoma*

\_\_\_ G1, well-differentiated

\_\_\_ G2, moderately differentiated

\_\_\_ G3, poorly differentiated

\_\_\_ GX, cannot be assessed: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Other*

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be assessed: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not applicable: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Tumor Size**

\_\_\_ Greatest dimension in Centimeters (cm): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

**+Additional Dimension in Centimeters (cm): \_\_\_\_ x \_\_\_\_ cm**

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Tumor Extent (Note** [**D**](#N7685)**) (select all that apply)**

\_\_\_ Noninvasive papillary carcinoma

\_\_\_ Urothelial carcinoma in situ

\_\_\_ Invades lamina propria (subepithelial connective tissue)

\_\_\_ Invades superficial muscularis propria (inner half)

\_\_\_ Invades deep muscularis propria (outer half)

\_\_\_ Invades perivesical soft tissue microscopically

\_\_\_ Invades perivesical soft tissue macroscopically (extravesical mass)

*# Use the Urethral checklist for tumors that involve the urethral mucosa without invasion, tumors that involve the urethral mucosa with invasion of subepithelial connective tissue / prostate stroma, or tumors that involve prostatic ducts and acini with or without stromal invasion.*

\_\_\_ Invades adjacent structure(s)#

\_\_\_ Prostatic stroma (transmural invasion from the bladder tumor) (Note [D](#N7685))

\_\_\_ Seminal vesicles

\_\_\_ Uterus

\_\_\_ Vagina

\_\_\_ Adnexa

\_\_\_ Pelvic wall

\_\_\_ Abdominal wall

\_\_\_ Rectum

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ No evidence of primary tumor

**Lymphatic and / or Vascular Invasion (Note** [**E**](#N7687)**)**

\_\_\_ Not identified

\_\_\_ Present

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Tumor Configuration (select all that apply)**

\_\_\_ Papillary

\_\_\_ Solid / nodule

\_\_\_ Flat

\_\_\_ Ulcerated

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Treatment Effect Post Neoadjuvant Chemotherapy (BCG not included)**

\_\_\_ No known presurgical neoadjuvant therapy

\_\_\_ Complete response: the absence of histologically identifiable residual cancer cells and extensive fibrosis of the tumor bed after presurgical neoadjuvant therapy (TRG1)

\_\_\_ Strong response: predominant fibrosis of the tumor bed with residual cancer cells occupying less than 50% of this area (TRG2)

\_\_\_ Weak and no response: residual cancer cells occupying greater than or equal to 50% of the tumor bed or absence of regressive changes (TRG3)

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Tumor Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**MARGINS (Note** [**F**](#N7686)**)**

**Margin Status for Invasive Tumor**

\_\_\_ All margins negative for invasive tumor

**+Closest Margin(s) to Invasive tumor (select all that apply)**

\_\_\_ Right ureteral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left ureteral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Urethral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Soft tissue: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*# For partial cystectomies, if the specimen is received unoriented precluding identification of specific margins, it*

*should be denoted here.*

\_\_\_ Other margin(s) (specify)#: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Distance from Invasive Tumor to Closest Margin**

*Specify in Millimeters (mm)*

\_\_\_ Exact distance: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ mm

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Invasive tumor present at margin

**+Margin(s) Involved by Invasive Tumor (select all that apply)**

\_\_\_ Right ureteral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left ureteral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Urethral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Soft tissue: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*# For partial cystectomies, if the specimen is received unoriented precluding identification of specific margins, it*

*should be denoted here.*

\_\_\_ Other margin(s) (specify)#: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not applicable

**Margin Status for Carcinoma in Situ / Noninvasive Papillary Urothelial Carcinoma**

*Non-invasive tumors include flat urothelial carcinoma in situ and non-invasive papillary urothelial carcinoma*

\_\_\_ All margins negative for carcinoma in situ / noninvasive papillary urothelial carcinoma

\_\_\_ Carcinoma in situ / noninvasive papillary urothelial carcinoma present at margin

**+Margin(s) Involved by Carcinoma in Situ / Noninvasive Papillary Urothelial Carcinoma (select**

**all that apply)**

\_\_\_ Right ureteral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left ureteral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Urethral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not applicable

**+Margin Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**REGIONAL LYMPH NODES**

**Regional Lymph Node Status**

\_\_\_ Not applicable (no regional lymph nodes submitted or found)

\_\_\_ Regional lymph nodes present

\_\_\_ All regional lymph nodes negative for tumor

\_\_\_ Tumor present in regional lymph node(s)

**Number of Lymph Nodes with Tumor**

\_\_\_ Exact number (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ At least (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Size of Largest Nodal Metastatic Deposit**

*Specify in Centimeters (cm)*

\_\_\_ Exact size: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

\_\_\_ At least (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

\_\_\_ Greater than: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

\_\_\_ Less than: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Nodal Site with Largest Metastatic Deposit (specify site): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**+Size of Largest Lymph Node with Tumor**

*Specify in Centimeters (cm)*

\_\_\_ Exact size: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

\_\_\_ At least (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

\_\_\_ Greater than: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

\_\_\_ Less than: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Largest Lymph Node with Tumor (specify site): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**+Extranodal Extension (ENE)**

\_\_\_ Not identified

\_\_\_ Present

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Specify Location of Involved Lymph Nodes: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Number of Lymph Nodes Examined**

\_\_\_ Exact number (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ At least (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Regional Lymph Node Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**DISTANT METASTASIS**

**Distant Site(s) Involved, if applicable#  (select all that apply)**

\_\_\_ Not applicable

\_\_\_ Non-regional lymph node(s): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other site(s), excluding non-regional lymph nodes (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**pTNM CLASSIFICATION (AJCC 8th Edition) (Note** [**G**](#N7688)**)**

*Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time the report is issued. As per the AJCC (Chapter 1, 8th Ed.) it is the managing physician’s responsibility to establish the final pathologic stage based upon all pertinent information, including but potentially not limited to this pathology report.*

**Modified Classification (required only if applicable)  (select all that apply)**

\_\_\_ Not applicable

\_\_\_ y (post-neoadjuvant therapy)

\_\_\_ r (recurrence)

**pT Category**

\_\_\_ pT not assigned (cannot be determined based on available pathological information)

\_\_\_ pT0: No evidence of primary tumor

\_\_\_ pTa: Non-invasive papillary carcinoma

\_\_\_ pTis: Urothelial carcinoma \*in situ\*: “flat tumor”

\_\_\_ pT1: Tumor invades lamina propria (subepithelial connective tissue)

*pT2: Tumor invades muscularis propria*

\_\_\_ pT2a: Tumor invades superficial muscularis propria (inner half)

\_\_\_ pT2b: Tumor invades deep muscularis propria (outer half)

\_\_\_ pT2 (subcategory cannot be determined)

*pT3: Tumor invades perivesical soft tissue*

\_\_\_ pT3a: Tumor invades perivesical soft tissue microscopically

\_\_\_ pT3b: Tumor invades perivesical soft tissue macroscopically (extravesicular mass)

\_\_\_ pT3 (subcategory cannot be determined)

*pT4: Extravesical tumor directly invades any of the following: prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall, abdominal wall*

\_\_\_ pT4a: Extravesical tumor invades directly into prostatic stroma, uterus, or vagina

\_\_\_ pT4b: Extravesical tumor invades pelvic wall, abdominal wall

\_\_\_ pT4 (subcategory cannot be determined)

**T Suffix (required only if applicable)**

\_\_\_ Not applicable

\_\_\_ (m) multiple primary synchronous tumors in a single organ

**pN Category**

\_\_\_ pN not assigned (no nodes submitted or found)

\_\_\_ pN not assigned (cannot be determined based on available pathological information)

\_\_\_ pN0: No lymph node metastasis

\_\_\_ pN1: Single regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node)

\_\_\_ pN2: Multiple regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node)

\_\_\_ pN3: Lymph node metastasis to the common iliac lymph nodes

**pM Category (required only if confirmed pathologically)**

\_\_\_ Not applicable - pM cannot be determined from the submitted specimen(s)

*pM1: Distant metastasis*

\_\_\_ pM1a: Distant metastasis limited to lymph nodes beyond the common iliacs

\_\_\_ pM1b: Non-lymph-node distant metastases

\_\_\_ pM1 (subcategory cannot be determined)

**ADDITIONAL FINDINGS**

**+Associated Epithelial Lesions (Note** [**C**](#N7684)**) (select all that apply)**

\_\_\_ None identified

\_\_\_ Urothelial papilloma

\_\_\_ Urothelial papilloma, inverted type

\_\_\_ Papillary urothelial neoplasm, low malignant potential (PUNLMP)

\_\_\_ Urothelial dysplasia

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Additional Findings (select all that apply)**

\_\_\_ Adenocarcinoma of prostate (use separate synoptic report for carcinoma of prostate)

\_\_\_ Inflammation / regenerative changes

\_\_\_ Therapy-related changes (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cystitis cystica et glandularis

\_\_\_ Keratinizing squamous metaplasia

\_\_\_ Intestinal metaplasia

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**COMMENTS**

**Comment(s): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Explanatory Notes**

**A. Sections for Microscopic Evaluation**

**Bladder**

Sections of bladder for microscopic evaluation for cystectomy specimens, several representative sections of the tumor, including the macroscopically deepest penetration, should be sampled. Submit several sections of the mucosa remote from the carcinoma, especially if abnormal, including the lateral wall(s), dome, and trigone. Submit one section of ureteral margin, unless submitted separately as frozen section specimens, and 1 section of urethral margin. If a long segment of the ureter(s) is present, then additional sections from the mid-portion may be necessary, as urothelial cancer often is multifocal. If no tumor is identified in the initial histologic sections, additional sampling should be done or submit the entire bladder lesion if feasible. In the post-neoadjuvant chemotherapy setting with no grossly identifiable lesion, all bladder sites should be sampled and correlation with the prior transurethral resection site(s) for sampling is encouraged.

**Prostate and Prostatic Urethra**

Prostatic urethral involvement should be carefully investigated in cystectomy specimens. Sections should include the prostatic urethra, including at the margin and with the surrounding prostatic parenchyma. Representative sections of the peripheral zone, central zone, and seminal vesicles should be included. Close gross examination may help target sampling of selective abnormal-appearing areas.

**Lymph Nodes**

Submit one section from each grossly positive lymph node. All other lymph nodes should be entirely submitted, as presence of nodal disease may be used as an indication for adjuvant therapy. Lymph nodes may be grossly or microscopically detected in the perivesical fat.

**Other Tissues**

Submit one or more sections of uterus (as indicated) and one or more sections of vagina, seminal vesicles, and other organs (as indicated). If the tumor grossly appears to invade the prostate, uterus, or vagina, sections should be targeted, such that the relationship of the infiltrating tumor in the bladder wall and the adjacent viscus is clearly demonstrable.

**B. Histologic Type**

The vast majority (more than 95%) of carcinomas of the urinary bladder are urothelial cell in origin.[1,](#R53302)[2,](#R53303)[3,](#R53304)[4,](#R33511)[5,](#R33512)[6,](#R33510)[7,](#R33509)[8](#R33513) The most recent 2022 World Health Organization (WHO) classification of epithelial tumors of the urothelial tract is provided in this note. Benign epithelial tumors are included in this classification because, within the same patient, a spectrum of differentiation from benign to malignant tumors may be seen in the bladder, either at the same time or over the clinical course of the disease.

Several subtypes (formerly variants) and divergent differentiations of invasive urothelial carcinoma are now recognized, and their presence should be documented. Invasive urothelial carcinoma subtypes such as sarcomatoid, micropapillary and plasmacytoid are recognized to be more aggressive. In cases of mixed urothelial subtypes and/or divergent differentiations, each component should be reported, including admixed neuroendocrine carcinoma if present. The distinction between a urothelial carcinoma with divergent squamous, glandular, or Müllerian differentiation and a pure squamous cell carcinoma, adenocarcinoma or Müllerian carcinoma is important. The 2022 WHO classification, require a pure histology of squamous cell carcinoma, adenocarcinoma or Müllerian to designate a tumor as such, all others with concomitant recognizable papillary, invasive, or flat carcinoma in situ (CIS) urothelial component being considered as urothelial carcinoma with divergent differentiation.

**2022 WHO Classification of Epithelial Tumors of the Urothelial Tract**  
  
Urothelial tumors  
Invasive urothelial carcinoma

Conventional urothelial carcinoma  
Urothelial carcinoma with squamous differentiation  
Urothelial carcinoma with glandular differentiation

Urothelial carcinoma with trophoblastic differentiation  
Nested urothelial carcinoma  
Tubular and microcystic urothelial carcinomas  
Micropapillary urothelial carcinoma  
Lymphoepithelioma-like urothelial carcinoma  
Plasmacytoid urothelial carcinoma  
Giant cell urothelial carcinoma  
Lipid-rich urothelial carcinoma  
Clear cell (glycogen-rich) urothelial carcinoma  
Urothelial carcinoma, poorly differentiated

Noninvasive urothelial lesions

Urothelial carcinoma in situ  
Noninvasive papillary urothelial carcinoma, high grade

Noninvasive papillary urothelial carcinoma, low grade

Papillary urothelial neoplasm of low malignant potential

Urothelial papilloma  
Inverted urothelial papilloma

Squamous cell neoplasms

Squamous cell carcinoma  
Verrucous carcinoma  
Squamous papilloma

Glandular neoplasms

Adenocarcinoma, NOS

Enteric

Mucinous  
Mixed  
Signet-ring cell  
Adenocarcinoma in situ

Villous adenoma  
Urachal and diverticular neoplasms

Urachal carcinoma  
Diverticular carcinoma

Tumors of Mullerian type  
Clear cell adenocarcinoma  
Endometrioid carcinoma  
  
Neuroendocrine neoplasms  
Small cell neuroendocrine carcinoma  
Large cell neuroendocrine carcinoma  
Mixed neuroendocrine neoplasm  
Well-differentiated neuroendocrine tumor  
Paraganglioma

References

1. WHO Classification of Tumours Editorial Board. Tumours of the urinary tract. In: WHO Classification of Tumours. Urinary and male genital tumours. 5th edition. Geneva, Switzerland: WHO Press; 2022.
2. Paner GP, Kamat, Netto GJ, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: grading of mixed grade, invasive urothelial carcinoma including histologic subtypes and divergent differentiations, and non-urothelial carcinomas. Am J Surg Pathol. 2023; online ahead of print.
3. Comperat E, Amin MB, Epstein JI, et al. The Genitourinary Pathology Society Update on classification of variant histologies, T1 substaging, molecular taxonomy, and immunotherapy and PD-L1 testing. Adv Anat Pathol. 2021;28:196-208.
4. Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Geneva, Switzerland: WHO Press; 2016.
5. Murphy WM, Grignon DJ, Perlman EJ. Tumors of the urinary bladder. In: Tumors of the Kidney, Bladder, and Related Urinary Structures. AFIP Atlas of Tumor Pathology. Series 4. Washington, DC: American Registry of Pathology; 2004.
6. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Tumors of the urinary system. In: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004.
7. Mostofi FK, Davis CJ, Sesterhenn IA. Histologic typing of urinary bladder tumors. In: World Health Organization International Histologic Classification of Tumours. 2nd ed. Heidelberg, Germany: Springer-Verlag, Berlin; 1999.
8. Epstein JI, Amin MB, Reuter VR, Mostofi FK, the Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology Consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22:1435-1448.

**C. Histologic Grade**

Flat intraepithelial lesions and papillary and invasive lesions are graded separately.[1,](#R53305)[2,](#R53306)[3,](#R53307)[4,](#R53308)[5,](#R33515)[6,](#R33514)[7,](#R33516)[8,](#R33517)[9](#R33519) In the 1973 WHO classification, papillary lesions were classified as papillomas and transitional cell carcinomas, grades 1, 2 and 3. Due to the need for a universally acceptable system, the World Health Organization/International Society of Urological Pathology (WHO/ISUP) consensus classification was proposed in 1998. This system is adopted in the 2004 WHO classification and has been validated by many studies to be prognostically significant. The 2016 WHO and 2022 WHO systems used essentially the same classification with minor modifications. Other systems may still be used according to institutional preference. Tumor grade according to both the 2004 WHO system and the 1973 WHO system may be concurrently used. The 2022 WHO system includes descriptive reporting of papillary urothelial carcinoma with mixed grades (low-grade with <5% high-grade component).

**2004 WHO/1998 ISUP Consensus Classification for Urothelial Lesions**  
  
Normal

Normal

Hyperplasia

Flat hyperplasia  
Papillary hyperplasia

Flat Lesions with Atypia

Reactive (inflammatory) atypia  
Atypia of unknown significance  
Dysplasia (low-grade intraurothelial neoplasia)#  
Carcinoma in situ (high-grade intraurothelial neoplasia)##

Papillary Neoplasms

Papilloma  
Inverted papilloma  
Papillary neoplasm of low malignant potential  
Papillary carcinoma, low-grade###  
Papillary carcinoma, high-grade###

Invasive Neoplasms

Lamina propria invasion  
Muscularis propria (detrusor muscle) invasion

#May include cases formerly diagnosed as “mild dysplasia.”

##Includes cases with “severe dysplasia.”

###Option exists to provide descriptive diagnosis on low grade papillary urothelial carcinoma with focal high-grade component.

The vast majority of invasive urothelial carcinoma are high-grade with uncommon cases of invasive low-grade tumors are reported, that usually have limited involvement of the lamina propria. Invasive urothelial carcinoma subtypes are graded as high-grade tumors, although these tumors should not be considered as a homogenous group in terms of behavior. Pure squamous carcinomas and adenocarcinomas are graded based on tumor differentiation as well-differentiated, moderately differentiated, and poorly differentiated.


References

1. WHO Classification of Tumours Editorial Board. Tumours of the urinary tract. In: WHO Classification of Tumours. Urinary and male genital tumours. 5th edition. Geneva, Switzerland: WHO Press; 2022.
2. Downes MR, Hartmann A, Shen A, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 1: comparison of bladder grading system performance. Am J Surg Pathol. 2023; online ahead of print
3. Paner GP, Kamat, Netto GJ, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: grading of mixed grade, invasive urothelial carcinoma including histologic subtypes and divergent differentiations, and non-urothelial carcinomas. Am J Surg Pathol. 2023; online ahead of print.
4. Amin MB, Comperat E, Epstein JI, et al. The Genitourinary Pathology Society update on classification and grading of flat and papillary urothelial neoplasia with new reporting recommendations and approach to lesions with mixed and early patterns of neoplasia. Adv Anat Pathol. 2021;28:179-195.
5. Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Geneva, Switzerland: WHO Press; 2016.
6. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Tumors of the urinary system. In: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004.
7. Murphy WM, Grignon DJ, Perlman EJ. Tumors of the urinary bladder. In: Tumors of the Kidney, Bladder, and Related Urinary Structures. AFIP Atlas of Tumor Pathology. Series 4. Washington, DC: American Registry of Pathology; 2004.
8. Epstein JI, Amin MB, Reuter VR, Mostofi FK, the Bladder Consensus Conference Committee. The World Health Organization/ International Society of Urological Pathology Consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22:1435-1448.
9. Mostofi FK. Histological typing of urinary bladder tumours. In: WHO Histological Classification of Tumours. No. 10. Geneva, Switzerland: World Health Organization; 1973.

**D. Extent of Invasion**

A critical role of the surgical pathologist is to diagnose the depth and extent of invasion into the subepithelial connective tissue/lamina propria/submucosa (pT1), muscularis propria (pT2), or beyond (pT3 or pT4).[1,](#R33524)[2,](#R53309)[3](#R53422) Depth of invasion is a critical prognostic determinant in invasive urothelial carcinoma. In cystectomy specimen, invasion into the muscularis propria should be subcategorized as pT2a and pT2b based on the depth of involvement. Note that pT2 is not applicable for cancers arising in diverticulum because of the lack of muscularis propria. Likewise, tumor extension into the perivesical tissue (pT3) should be subcategorized into pT3a and pT3b, the latter best assessed on gross examination by the identification of macroscopic involvement of the perivesical tissue.

Involvement of the prostate gland may occur in several different patterns. Tumors (carcinoma in situ, papillary or invasive carcinoma) can first spread along the prostatic urethral mucosa and prostate glands and subsequently invade prostatic stroma (transurethral mucosal route) (Figure 1). Tumors may also invade through the bladder wall and the base of the prostate directly into the prostate gland. Tumors can also invade into extravesical fat and then extend back into the prostate gland. The latter two routes are considered direct transmural invasion. The AJCC 8th edition staging manual defines direct extension of urinary bladder cancer into the prostate gland as pT4 disease and excludes transurethral mucosal prostatic stroma invasion from the pT4a staging status. However, there is limited data on the best methodology to stage urothelial carcinoma that concurrently involves the urinary bladder and the prostatic urethra. In patients who have a large urinary bladder carcinoma that has invaded through the full thickness of the bladder wall and thereby secondarily involves the prostatic stroma, a pT4 stage should be assigned per urinary bladder staging. In other circumstances in which involvement by urothelial carcinoma is seen in both sites, separate urinary bladder and prostatic urethral staging should be assigned. Transmucosal route into prostatic stroma from a bladder cancer without transmural prostatic stromal invasion is now categorized as pT2 per urethral cancer staging, and the concomitant bladder proper cancer is given a separate stage category according to the bladder cancer staging.



**Figure 1.**Prostatic invasion from urinary bladder cancer via direct transmural and extravesical route (pT4 bladder staging) and transurethral invasion (pT2 urethral staging). From: Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017. Reproduced with permission.

References

1. Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.
2. Comperat E, Amin MB, Epstein JI, et al. The Genitourinary Pathology Society Update on classification of variant histologies, T1 substaging, molecular taxonomy, and immunotherapy and PD-L1 testing. Adv Anat Pathol. 2021;28:196-208.
3. Paner GP, Montironi R, Amin MB. Challenges in pathologic staging of bladder cancer: proposals for fresh approaches of assessing pathologic stage in light of recent studies and observations pertaining to bladder histoanatomic variances. Adv Anat Pathol. 2017;3:113-127.

**E. Lymphatic and/or Vascular Invasion**

Urothelial carcinoma may invade blood vessels or lymphatic channels. Lymphatic and/or vascular invasion has been shown to be an independent predictor of recurrence and decreased overall survival.[1,](#R53311)[2,](#R53313)[3](#R53312) Presence of lymph-vascular invasion in TURBT specimens is associated with higher nodal metastasis. In suspicious cases, blood vessels can be highlighted by immunohistochemical staining for factor VIII-related antigen, CD31 or CD34. Staining will not resolve the problem of differentiating lymphatic versus artifactual space entrapment by tumor cells, and as mentioned, this is frequently seen in urothelial tumors invading the lamina propria. Retraction artifact is also prominent in micropapillary urothelial carcinoma.

References

1. Werntz RP, Smith ZL, Packiam VT, et al. The impact of lymphovascular invasion on risk of upstaging and lymph node metastasis at the time of radical cystectomy. Eur Urol Focus. 2020;15:292-297.
2. Mari A, Kimura S, Foerster B, et al. A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer. Urol Oncol. 2018;36:293-305.
3. Lotan Y, Gupta  A, Shariat SF, et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in  patients with negative lymph nodes at radical cystectomy. J Clin Oncol. 2005;23:6533-6539.

**F. Margins**

Resection margins, including those mentioned in Note A, should be carefully specified. Statements about deep soft tissue margins should specify whether peritoneal surfaces are involved by tumor. Soft tissue margin location if identifiable should be documented. In cases of partial cystectomy, the bladder wall cut margin should be assessed. It is not an uncommon practice for surgeons to submit the distal ureters as separate margins.


**G. TNM and Stage Groupings**

The TNM Staging System for carcinomas of the urinary bladder of the AJCC is recommended.[1](#R33538) A cystoprostatectomy specimen may contain three separate primaries: carcinoma of the urinary bladder, carcinoma of the prostate and carcinoma of the urethra. Depending on the pathology in a given case, the number of protocols to be used in a cystoprostatectomy specimen will vary.

By AJCC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible. Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (e.g., when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

**Primary Tumor (T)** (Figure 2)

The suffix “m” should be added to the appropriate T category to indicate multiple tumors. The suffix “is” may be added to any T to indicate the presence of associated carcinoma in situ.



**Figure 2.**  Extent of Tis, Ta, T1, and T3. From: Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017. Reproduced with permission.

**TNM Descriptors**

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y” and “r” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (i.e., before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

References

1. Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.